Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC

Elise A Olsen, Sean Whittaker, Rein Willemze, Lauren Pinter-Brown, Francine Foss, Larisa Geskin, Lawrence Schwartz, Steven Horwitz, Joan Guitart, John Zic, Youn H Kim, Gary S Wood, Madeleine Duvic, Wei Ai, Michael Girardi, Alejandro Gru, Emmanuella Guenova, Emmilia Hodak, Richard Hoppe, Werner Kempf, Ellen Kim, Mary Jo Lechowicz, Pablo Ortiz-Romero, Evangelia Papadavid, Pietro Quaglino, Mark Pittelkow, H Miles Prince, Jose Antonio Sanches, Makoto Sugaya, Maarten Vermeer, Jasmine Zain, Robert Knobler, Rudolf Stadler, Martine Bagot, Julia Scarisbrick, Elise A Olsen, Sean Whittaker, Rein Willemze, Lauren Pinter-Brown, Francine Foss, Larisa Geskin, Lawrence Schwartz, Steven Horwitz, Joan Guitart, John Zic, Youn H Kim, Gary S Wood, Madeleine Duvic, Wei Ai, Michael Girardi, Alejandro Gru, Emmanuella Guenova, Emmilia Hodak, Richard Hoppe, Werner Kempf, Ellen Kim, Mary Jo Lechowicz, Pablo Ortiz-Romero, Evangelia Papadavid, Pietro Quaglino, Mark Pittelkow, H Miles Prince, Jose Antonio Sanches, Makoto Sugaya, Maarten Vermeer, Jasmine Zain, Robert Knobler, Rudolf Stadler, Martine Bagot, Julia Scarisbrick

Abstract

The number of patients with primary cutaneous lymphoma (PCL) relative to other non-Hodgkin lymphomas (NHLs) is small and the number of subtypes large. Although clinical trial guidelines have been published for mycosis fungoides/Sézary syndrome, the most common type of PCL, none exist for the other PCLs. In addition, staging of the PCLs has been evolving based on new data on potential prognostic factors, diagnosis, and assessment methods of both skin and extracutaneous disease and a desire to align the latter with the Lugano guidelines for all NHLs. The International Society for Cutaneous Lymphomas (ISCL), the United States Cutaneous LymphomaConsortium (USCLC), and the Cutaneous Lymphoma Task Force of the European Organization for the Research and Treatment of Cancer (EORTC) now propose updated staging and guidelines for the study design, assessment, endpoints, and response criteria in clinical trials for all the PCLs in alignment with that of the Lugano guidelines. These recommendations provide standardized methodology that should facilitate planning and regulatory approval of new treatments for these lymphomas worldwide, encourage cooperative investigator-initiated trials, and help to assess the comparative efficacy of therapeutic agents tested across sites and studies.

© 2022 by The American Society of Hematology.

Figures

Figure 1.
Figure 1.
Regional areas of the body for assessment of total body skin lesions. Body region percent BSA for mSWAT determination by Lund and Browder. A, B, and C designate the body regions of head, thigh, and leg, respectively, for which they provided adjustments in BSA for children aged 1 to 5 years.
Figure 2.
Figure 2.
Revised nodal drainage areas for determination of classification of skin involvement in non-MF/non-SS PCLs. The nodal regions (based on the Ann Arbor classification) and their boundaries are as follows: head and neck (HN), inferior borders = clavicles anterior and T1 spinous process posterior; left upper arm (LUA), superior border = glenohumeral joint (exclusive of axilla), inferior border = ulnar/radial/humeral (elbow) joint; left lower arm and hand (LLAH), superior border = ulnar/radial/humeral (elbow) joint; right upper arm (RUA), superior border = glenohumeral joint (exclusive of axilla), inferior border = ulnar/radial/humeral (elbow) joint; right lower arm and hand (RLAH), superior border = ulnar/radial/humeral (elbow) joint; chest (C), superior border = superior border clavicles, inferior border = inferior margin rib cage, lateral borders = midaxillary lines and glenohumeral joints (inclusive of axilla); abdomen/genital (AG), superior border = inferior margin rib cage, inferior border = inguinal folds and anterior perineum; upper back (UB), superior border = T1 spinous process, inferior border = inferior margin rib cage, lateral borders = midaxillary lines; lower back/buttocks (LBB), superior border = inferior margin rib cage, inferior border = inferior gluteal fold and anterior perineum (inclusive of perineum), lateral borders = midaxillary lines; left upper leg (LUL), superior border = inguinal fold and gluteal folds, inferior border = midpatella anterior and mid–popliteal fossa posterior; left lower leg and foot (LLLF), superior border = midpatella anterior and mid–popliteal fossa posterior; right upper leg (RUL), superior border = inguinal fold and gluteal folds, inferior border = midpatella anterior and mid–popliteal fossa posterior; right lower leg and foot (RLLF), superior border = midpatella anterior and mid–popliteal fossa posterior.

References

    1. Willemze R, Jaffe ES, Burg G, et al. . WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768-3785.
    1. Willemze R, Cerroni L, Kempf W, et al. . The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703-1714.
    1. Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009;113(21):5064-5073.
    1. Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol. 2007;143(7):854-859.
    1. Wilson LD, Hinds GA, Yu JB. Age, race, sex, stage, and incidence of cutaneous lymphoma. Clin Lymphoma Myeloma Leuk. 2012;12(5):291-296.
    1. Cook LB, Fuji S, Hermine O, et al. . Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. J Clin Oncol. 2019;37(8):677-687.
    1. Olsen E, Vonderheid E, Pimpinelli N, et al. ; ISCL/EORTC . Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6): 1713-1722.
    1. Olsen EA, Whittaker S, Kim YH, et al. ; Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer . Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011;29(18): 2598-2607.
    1. Kim YH, Willemze R, Pimpinelli N, et al. ; ISCL and the EORTC . TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(2):479-484.
    1. Kempf W, Pfalz K, Vermeer MH, et al. . EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011;118(15): 4024-4035.
    1. Cheson BD, Fisher RI, Barrington SF, et al. ; United Kingdom National Cancer Research Institute . Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068.
    1. van Dongen JJM, Langerak AW, Brüggemann M, et al. . Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17(12):2257-2317.
    1. van Krieken JH, Langerak AW, Macintyre EA, et al. . Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia. 2007;21(2):201-206.
    1. Morales AV, Arber DA, Seo K, Kohler S, Kim YH, Sundram UN. Evaluation of B-cell clonality using the BIOMED-2 PCR method effectively distinguishes cutaneous B-cell lymphoma from benign lymphoid infiltrates. Am J Dermatopathol. 2008;30(5):425-430.
    1. Hodak E, Sherman S, Papadavid E, et al. ; Cutaneous Lymphoma International Consortium (CLIC) institutions . Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study. Br J Dermatol. 2021; 184(3):524-531.
    1. Pimpinelli N, Olsen EA, Santucci M, et al. ; International Society for Cutaneous Lymphoma . Defining early mycosis fungoides. J Am Acad Dermatol. 2005;53(6):1053-1063.
    1. Hodak E, Amitay-Laish I, Atzmony L, et al. . New insights into folliculotropic mycosis fungoides (FMF): A single-center experience. J Am Acad Dermatol. 2016;75(2):347-355.
    1. Scarisbrick JJ, Prince HM, Vermeer MH, et al. . Cutaneous Lymphoma International Consortium study of outcome in advanced stages of mycosis fungoides and Sézary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol. 2015;33(32):3766-3773.
    1. Oken MM, Creech RH, Tormey DC, et al. . Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-655.
    1. Molloy K, Jonak C, Woei-A-Jin FJSH, Guenova E, Busschots AM, Bervoets A, et al. . Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study. Br J Dermatol. 2020;182(3):770-779.
    1. Jonak C, Porkert S, Oerlemans S, et al. . Health-related Quality of Life in Cutaneous Lymphomas: Past, Present and Future. Acta Derm Venereol. 2019;99(7):640-646.
    1. Demierre MF, Gan S, Jones J, Miller DR. Significant impact of cutaneous T-cell lymphoma on patients’ quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey. Cancer. 2006;107(10):2504-2511.
    1. Herbosa CM, Semenov YR, Rosenberg AR, Mehta-Shah N, Musiek AC. Clinical severity measures and quality of life burden in patients with mycosis fungoides and Sezary syndrome: comparison of generic and dermatology–specific instruments. J Eur Acad Dermatol Venereol. 2020;34(5): 995-1003.
    1. Cella DF, Tulsky DS, Gray G, et al. . The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570-579.
    1. Chren MM. Quality of care in dermatology. The state of (measuring) the art. Arch Dermatol. 1997;133(11):1349-1351.
    1. Olsen E, Duvic M, Frankel A, et al. . Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001;19(2):376-388.
    1. Olsen EA, Kim YH, Kuzel TM, et al. . Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(21):3109-3115.
    1. Duvic M, Martin AG, Kim Y, et al. ; Worldwide Bexarotene Study Group . Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001;137(5):581-593.
    1. Scarisbrick JJ, Morris S. How big is your hand & should you use it to score skin in cutaneous T-cell lymphoma? Br J Dermatol. 2013;169(2):260-265.
    1. Lund CC, Browder NC. The estimation of areas of burns. Surg Gynecol Obstet. 1944;79:352-358.
    1. AJCC . AJCC Cancer Staging Manual, 6th ed. New York, NY: Springer; 2002.
    1. Lessin SR, Duvic M, Guitart J, et al. . Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol. 2013;149(1):25-32.
    1. Dan S, Qiang G, Shu-Xia W, Chang-Hong L. Preliminary discussion on the value of (18)F-FDG PET/CT in the diagnosis and early staging of non-mycosis fungoides/Sézary’s syndrome cutaneous malignant lymphomas. Eur J Radiol. 2015;84(7):1293-1298.
    1. Alanteri E, Usmani S, Marafi F, et al. . The role of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with mycosis fungoides. Indian J Nucl Med. 2015; 30(3):199-203.
    1. Tsai EY, Taur A, Espinosa L, et al. . Staging accuracy in mycosis fungoides and Sézary syndrome using integrated positron emission tomography and computed tomography. Arch Dermatol. 2006;142(5):577-584.
    1. Brix G, Lechel U, Glatting G, et al. . Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. J Nucl Med. 2005;46(4):608-613.
    1. Optimizing Oncologic FDG-PET/CT Scans to Decrease Radiation Exposure. .
    1. Wu X, Pertovaara H, Korkola P, Vornanen M, Eskola H, Kellokumpu-Lehtinen PL. Glucose metabolism correlated with cellular proliferation in diffuse large B-cell lymphoma. Leuk Lymphoma. 2012;53(3):400-405.
    1. Battistella M, Sallé de Chou C, de Bazelaire C, et al. . Lymph node image-guided core-needle biopsy for cutaneous T-cell lymphoma staging. Br J Dermatol. 2016;175(6):1397-1400.
    1. Kiliçarslan A, Doğan M, Süngü N, et al. . Can cutting-needle biopsy be an alternative to excisional biopsy in lymph node pathologies? Turk Patoloji Derg. 2017;1(1):235-239.
    1. Groneck L, Quaas A, Hallek M, Zander T, Weihrauch MR. Ultrasound-guided core needle biopsies for workup of lymphadenopathy and lymphoma. Eur J Haematol. 2016;97(4):379-386.
    1. Scarisbrick JJ, Hodak E, Bagot M, et al. . Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force. Eur J Cancer. 2018;93:47-56.
    1. Scarisbrick JJ, Hodak E, Bagot M, et al. . Developments in the understanding of blood involvement and stage in mycosis fungoides/Sezary syndrome. Eur J Cancer. 2018;101:278-280.
    1. Rajkumar SV, Harousseau J-L, Durie B, et al. ; International Myeloma Workshop Consensus Panel 1 . Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691-4695.
    1. Abrouk M, Nakamura M, Zhu TH, Farahnik B, Koo J, Bhutani T. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients. J Dermatolog Treat. 2017;28(6):488-491.
    1. Olsen EA, Kornacki D, Sun K, Hordinsky MK. Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study. J Am Acad Dermatol. 2020;82(2):412-419.
    1. Oxnard GR, Zhao B, Sima CS, et al. . Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. J Clin Oncol. 2011;29(23):3114-3119.
    1. Yoon SH, Kim KW, Goo JM, Kim D-W, Hahn S. Observer variability in RECIST-based tumour burden measurements: a meta-analysis. Eur J Cancer. 2016;53:5-15.
    1. Zhao B, James LP, Moskowitz CS, et al. . Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. Radiology. 2009;252(1):263-272.
    1. Juweid ME, Stroobants S, Hoekstra OS, et al. ; Imaging Subcommittee of International Harmonization Project in Lymphoma . Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25(5):571-578.
    1. Cheson BD, Ansell S, Schwartz L, et al. . Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016;128(21):2489-2496.
    1. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. . Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group [published correction appears in J Clin Oncol. 2016;34(21):2562]. J Clin Oncol. 2014;32(27):3048-3058.
    1. Prince HM, Kim YH, Horwitz SM, et al. ; ALCANZA study group . Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555-566.
    1. Campbell BA, Scarisbrick JJ, Kim YH, Wilcox RA, McCormack C, Prince HM. Time to next treatment as a meaningful endpoint for trials of primary cutaneous lymphoma. Cancers (Basel). 2020;12(8):2311.
    1. Cheson BD, Pfistner B, Juweid ME, et al. . Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579– 586.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera